Invasive procedures like PET & Spinal Tap have an impact on patient willingness to participate in a clinical trial.
Imeka’s non-invasive technology adds a positive value to patient’s desire to participate in a clinical trial.
Furthermore, diffusion MRI can generate AFD (Apparent Fiber Density) markers that correlate with NFL (Neurofilament light), enabling a more precise tracking of patient’s changes, without needing biological samples.
Free-water is a localized proxy sensitive to neuroinflammation which can be used for better drug selection and drug effect assessment. This proxy correlates with Beta Amyloid PET gold standard.